2. Academic Validation
  3. STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity

STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity

  • Nature. 2025 May 14. doi: 10.1038/s41586-025-09000-3.
Jiajia Zhou 1 2,  Kole Tison 1 2 3 4,  Haibin Zhou 5,  Longchuan Bai 5,  Ranjan Kumar Acharyya 5,  Donna McEachern 5,  Hoda Metwally 5,  Yu Wang 5,  Michael Pitter 1 2,  Jae Eun Choi 6 7,  Linda Vatan 1 2,  Peng Liao 1 2,  Jiali Yu 1 2,  Heng Lin 1 2,  Long Jiang 2 4,  Shuang Wei 1 2,  Xue Gao 1 2,  Sara Grove 1 2,  Abhijit Parolia 6 7,  Marcin Cieslik 4 6 7,  Ilona Kryczek 1 2,  Michael D Green 2 8,  Jian-Xin Lin 9,  Arul M Chinnaiyan 6 7 10 11 12,  Warren J Leonard 9,  Shaomeng Wang 13 14 15 16 17,  Weiping Zou 18 19 20 21 22 23
Affiliations

Affiliations

  • 1 Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
  • 2 Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
  • 3 Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA.
  • 4 Department of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI, USA.
  • 5 Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
  • 6 Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
  • 7 Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
  • 8 Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
  • 9 Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
  • 10 Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI, USA.
  • 11 University of Michigan Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
  • 12 Graduate Program in Cancer Biology, University of Michigan, Ann Arbor, MI, USA.
  • 13 Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA. shaomeng@umich.edu.
  • 14 Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. shaomeng@umich.edu.
  • 15 University of Michigan Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. shaomeng@umich.edu.
  • 16 Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA. shaomeng@umich.edu.
  • 17 Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. shaomeng@umich.edu.
  • 18 Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA. wzou@umich.edu.
  • 19 Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA. wzou@umich.edu.
  • 20 Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA. wzou@umich.edu.
  • 21 Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. wzou@umich.edu.
  • 22 University of Michigan Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. wzou@umich.edu.
  • 23 Graduate Program in Cancer Biology, University of Michigan, Ann Arbor, MI, USA. wzou@umich.edu.
PMID: 40369063 DOI: 10.1038/s41586-025-09000-3
Abstract

Immune checkpoint blockade (ICB) has transformed Cancer therapy1,2. The efficacy of immunotherapy depends on dendritic cell-mediated tumour antigen presentation, T cell priming and activation3,4. However, the relationship between the key transcription factors in dendritic cells and ICB efficacy remains unknown. Here we found that ICB reprograms the interplay between the STAT3 and STAT5 transcriptional pathways in dendritic cells, thereby activating T cell immunity and enabling ICB efficacy. Mechanistically, STAT3 restrained the JAK2 and STAT5 transcriptional pathway, determining the fate of dendritic cell function. As STAT3 is often activated in the tumour microenvironment5, we developed two distinct PROTAC (proteolysis-targeting chimera) degraders of STAT3, SD-36 and SD-2301. STAT3 degraders effectively degraded STAT3 in dendritic cells and reprogrammed the dendritic cell-transcriptional network towards immunogenicity. Furthermore, STAT3 Degrader monotherapy was efficacious in treatment of advanced tumours and ICB-resistant tumours without toxicity in mice. Thus, the crosstalk between STAT3 and STAT5 transcriptional pathways determines the dendritic cell phenotype in the tumour microenvironment and STAT3 degraders hold promise for Cancer Immunotherapy.

Figures
Products